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period 2001-2007. Methods: A logistic regression was performed aspatially and at 
the nodes of a 5 km spacing grid overlaid over Florida and using all the cancer cases 
within a radius of 125 km of each node. Each observation was weighted as a function 
of its proximity to the center of the window (bisquare adaptive weight function). 
Covariates included age, race, marital status, smoking, type of health insurance 
and diagnosis facilities, presence of comorbidities (healthy (no comorbidity), aver-
age (1-2 comorbidities), above-average), census-tract median income and presence 
of farmhouse, year of diagnosis, county-level provider-to-case ratios. Results: 
Variables increasing the likelihood of late-stage diagnosis included having 1 to 2 
comorbidities (odds= 1.697) and more than 2 comorbidities (odds= 3.963), smoking 
(odds= 1.283), being African American (odds= 1.199) and living in census tracts with 
farmhouses (odds= 1.124). Having private insurance (odds= 0.533), having public 
insurance (odds= 0.470), being married (odds= 0.787) or diagnosed in a for-profit 
facility (odds= 0.886), as well as living in census tracts with high income (odds= 0.994) 
reduces the likelihood. ConClusions: There are significant spatial associations 
between late-stage prostate cancer incidence and observed individual, socioeco-
nomic, behavioral, environmental and demographic factors in Florida. This empha-
sizes the need for local strategies and cancer control interventions to reduce the 
percentage of late-stage diagnosis and ultimately eliminate health disparities.
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objeCtives: Differences in cancer incidence and mortality are apparent among vari-
ous demographic groups. Understanding the underlying determinants that place cer-
tain population subgroups at higher incidence and/or mortality of prostate cancer is 
imperative. Analyzing temporal trends can provide a comprehensive picture of the 
burden of the disease and generate new insights about the impact of various interven-
tions. This study aims to use advanced geospatial and temporal statistical techniques 
to model temporal trends in prostate cancer incidence and mortality and their geo-
graphical variations across Florida. Methods: Annual census-tract level rates were 
computed over the period 1981-2007 for two races (white and black), two categories of 
age (40-65, > 65) and five classes of incomes. They were then smoothed using binomial 
kriging to filter the noise caused by small population sizes. Joinpoint regression and new 
disparity statistics were applied to analyze temporal trends and detect potential racial 
and socio-economic differences. Results: Bivariate analysis of time-series indicated 
that late-stage diagnosis was generally more prevalent among blacks compared to 
whites, for age category 40-64 compared to older patients who are covered by Medicare, 
and among classes of lower socio-economic status. Joinpoint regression showed that 
the rate of decline in late-stage diagnosis for the two racial groups was similar among 
older patients (i.e. parallel time series). Both races displayed distinct spatial patterns 
with higher rates of late-stage diagnosis in the Florida Panhandle for white males 
whereas high rates clustered in South-eastern Florida for black males. ConClusions: 
The observed impact of socioeconomic and demographic factors on temporal trends 
in health outcomes emphasizes the need for local strategies and cancer control inter-
ventions to reduce late-stage diagnosis and improve health outcomes. Furthermore, 
large variations in the temporal trends in prostate cancer incidence and mortality and 
geographical variations would have important implications for resource allocation.
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objeCtives: Increased comorbid/mortality risk accompanies both excess weight 
and cancer. Charlson comorbidity index (CCI) scores in obesity and cancer 
were examined across two distinct populations and study designs. Methods: 
Comprehensive, electronic medical record (EMR) 2013 data from Clalit, a payer-
provider, closed-system health fund covering 55% of the Israeli population, were 
used to assess cancer diagnosis (vs. no cancer) and obesity (BMI≥ 30 vs. less) among 
individuals aged 21+ in Israel (n= 2,552,720). Similarly examined were 2013 adult 
(21+) respondents in the U.S. NHWS (n= 71,118), a cross-sectional, self-reported 
online survey. CCI, a weighted sum of comorbidities predicting mortality risk, was 
calculated based on registry diagnostic codes (Clalit) or self-reported diagnosis 
(NHWS). CCI categories and mean scores were compared across obesity/cancer 
groups and within age strata. Results: Proportions or patterns of individuals with 
CCI= 1+ were comparable across age brackets (21-49, 50-64, 65+) in Clalit (10.5%, 
43.3%, 66.7%, respectively) and NHWS (14.1%, 33.1%, 44.3%). CCI was higher among 
those with vs. without cancer (or obese vs. non-obese), all p< 0.05, among both 
Israeli (Clalit) and U.S. (NHWS) individuals. Across non-obesity/non-cancer, obesity/
non-cancer, non-obesity/cancer, and obesity/cancer groups, significantly increasing 
proportions of individuals had CCI= 1+ in both Clalit (23.4%, 41.9%, 68.7%, 77.2%, 
respectively) and NHWS (16.7%, 31.3%, 56.5%, 70.0%), plus increasing CCI means in 
Clalit (0.40, 0.80, 1.80, 2.10) and NHWS (0.25, 0.45, 1.38, 1.73), all p< 0.05. These pat-
terns replicated within the different age brackets. ConClusions: Across distinct 
data sources (Israeli insurance-clinical EMR and U.S. online survey), comparable 
comorbidity rates emerged within corresponding age brackets (notwithstanding 
“healthy cohort” effects observed among NHWS respondents aged 65+), and similar 
patterns of increased risk emerged with both cancer and obesity. This underscores 
the global challenge posed by the “dual-risk” profile of obesity with cancer history. 
Moreover, comprehensive and integrated EMR data can produce convergent results 
with validated, self-reported data, across diverse geographies.
age with mechanical stapling – which has potential to improve patient outcomes, 
lower re-operation rates and lower costs.
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objeCtives: Lung cancer is the first cause of cancer death in both men and women 
worldwide and 85% are NSCLC. As a targeted therapy for NSCLC, EGFR-TKIs has been 
compared with traditional chemotherapy in various trials in different countries 
but there is a lack of comprehensive literature review of these RCTs especially 
from Health-Related Quality of Life (HRQoL) perspective. We compared the effi-
cacy, safety and HRQoL between EGFR-TKIs(gefitinib, erlotinib and afatinib) and 
chemotherapy for advanced NSCLC patients with largest magnitude. Methods: 
Two authors independently searched published RCTs comparing EGFR-TKIs vs 
chemotherapy for advanced NSCLC between Jan 1, 1966 and July 31, 2013 in PubMed, 
Cochrane Library, EMBASE, the conference proceedings of ASCO and ESMO. We con-
ducted meta-analysis by Revman 5.0 using either random or fixed effects inverse 
variance weighted method, determined by heterogeneity levels. Results: Twenty-
two eligible studies and 6728 patients were included. Comparing to chemotherapy, 
EGFR-TKIs were superior in objective response rate (OR= 1.90, 95% CI= 1.32-2.57, 
P< 0.00001) and progression free survival (HR= 0.78, 95%CI= 0.66-0.91, P< 0.00001). 
However, no significant differences were observed on disease control rate (OR: 1.24; 
95% CI= 0.89-1.73), median overall survival (HR= 1.00; 95%CI= 0.93-1.07) and 1-yr 
survival rate (OR= 0.96; 95% CI = 0.82-1.13). EGFR-TKIs demonstrated less adverse 
events in neutropenia (OR= 0.01, 95% CI= 0.01-0.02), anemia (OR= 0.2, 95% CI= 0.14-
0.31), fatigue (OR= 0.18, 95% CI= 0.12-0.29) and nausea (OR= 0.35, 95% CI= 0.21-0.60) 
and less grade 3 or 4 adverse events (OR= 0.29, 95%CI= 0.26-0.33). However, chemo-
therapy had less rash (OR= 7.18, 95% CI= 4.67-11.05) and diarrhea (OR= 2.10, 95% 
CI= 1.49-2.98). In 8 studies evaluating the HRQoL, EGFR-TKIs had shown better out-
comes than chemotherapy according to the three HRQoL instruments: Functional 
Assessment of Cancer Therapy-Lung (OR= 1.62, 95% CI= 1.38-1.91), Trial Outcome 
Index (OR= 1.93, 95%CI= 1.61- 2.33), and Lung Cancer Subscale (OR= 1.19, 95%CI= 1.01-
1.39). ConClusions: Though no obvious survival benefit was observed, EGFR-TKIs 
demonstrated significantly better safety and HRQoL outcomes than chemotherapy.
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objeCtives: To determine the comorbidity burden and the association of specific 
pre-existing chronic-conditions with colorectal cancer (CRC) stage-at-diagnosis, 
treatment, and survival among elderly Medicare beneficiaries from a rural popula-
tion. Methods: This population-based retrospective cohort study used data on 
fee-for-service Medicare beneficiaries diagnosed with CRC and chronic-conditions 
between 2003-2006, identified from the West Virginia Cancer Registry (WVCR)-
Medicare linked database (n= 2,119). Beneficiaries were classified in specific chronic-
condition clusters. CRC-treatment received was ascertained from beneficiaries’ 
Medicare claims by following them for 12-months from their CRC-diagnosis date 
or until death. Receipt of minimally-appropriate CRC treatment (MACT) as defined 
by National Cancer Institute CRC-treatment guidelines and receipt of CRC-related 
surgery, chemotherapy, and radiation were examined. All-cause and CRC-specific 
mortality in the 36-month period following the CRC-diagnosis were examined, 
after accounting for selection bias using inverse probability treatment weights and 
adjusting for socio-demographics, cancer site and stage-at-diagnosis, receipt of 
MACT, and pre-existing conditions. Results: The WVCR-Medicare linked data-
base had a higher proportion of beneficiaries as compared to those from national 
data across almost all the condition clusters including previous-malignancy, COPD, 
depression, gastrointestinal conditions, heart-conditions, hypertension, liver-
conditions, and renal-conditions. Beneficiaries from the WVCR-Medicare linked 
database with most chronic-conditions were generally not likely to be diagnosed at 
distant-stage CRC, and possibly not as less aggressively treated for CRC as reported 
by some other studies. Only a few conditions were negatively associated with CRC-
specific mortality including depression (adjusted hazards ratio (AHR)= 1.25;95%CI
= [1.08,1.46]), and liver-conditions (AHR= 1.38;95%CI= [1.19,1.60]). However, almost 
all chronic-conditions were negatively associated with all-cause mortality in this 
study. ConClusions: This study highlights the need to focus on cancer-care that 
is better integrated with co-management of chronic-conditions, especially among 
those from rural-areas who are likely to have a high comorbidity burden.
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objeCtives: To account for the non-stationarity of relationships in space, aspatial 
regression can be supplemented with geographically-weighted regression (GWR), 
whereby the regression model is fitted within local windows and each observation 
is weighted according to its proximity to the center of the window. This study aims 
to conduct regression analysis in a spatial context to assess the local impacts of 
putative factors on late-stage diagnosis of prostate cancer in Florida during the 
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objeCtives: FDA accelerated approvals for some chemotherapies used PFS as an OS 
surrogate. However, one mBC approval was revoked after OS gains were not observed 
post-approval. We compared PFS with OS by first-line (1L) chemotherapy using 
real world evidence from US mBC patients. Methods: IMS Health Comprehensive 
Disease Records for Breast Cancer link IMS PharMetrics Plus, oncology EMRs, and 
Social Security Death Index. Female breast cancer patients (ICD-9-CM 174.x, 233.0) 
were selected with index metastasis (ICD-9-CM 196.x-198.x or EMR Stage IV) 
7/1/2006-3/31/2012, age ≥ 18, no HR overexpression, 1L chemotherapy (anthracy-
clines or txanes [AT] or new cytotoxic agents [NCA]), enrollment 180 days pre-index 
and ≥ 30 days post-index, and no other malignancies. PFS proxy was 1L duration; 
OS was measured until death or censoring (end of enrollment). Log-rank analysis 
compared PFS by 1L treatment. A Cox proportional hazards model assessed post-1L 
OS by 1L chemotherapy and duration, propensity for NCA vs. AT, HER2 status, and 
patient characteristics. Results: Of 845 mBC patients, 334 met study criteria (mean 
[SD] age= 51.7 [8.7] years, 20.4% HER2+). Propensity for NCA (n= 70) vs. AT (n= 264) 
increased with diabetes history (OR= 2.79, 95% CI 1.12-6.90) and higher pre-index 
health care expenditures (OR= 1.27, 95% CI 1.05-1.54). 1L NCAs were administered 
a mean (median) 195.2 (73.0) days (anthracyclines 53.5 [44.0], taxanes 122.2 [47.5], 
-2Log LR 54.3, 2 df, p< .0001). Cox regression estimated that 30 additional days of 
1L chemotherapy predicted slightly shorter post-1L OS (HR= 1.03, 95% CI 1.00-1.06); 
NCA (vs. AT) predicted stronger decreases in post-1L OS (HR= 2.32, 95% CI 1.11-4.86) 
despite propensity adjustment. ConClusions: Duration of 1L chemotherapy, as 
a proxy for PFS, predicted slightly shorter post-1L OS. Choice of 1L chemotherapy 
was a stronger predictor of post-1L OS, adjusted for selection bias. Real world data 
suggests that PFS is a poor OS surrogate in mBC.
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objeCtives: Phase 3 oncology clinical trials have had success rates of 41% 
(Djulbegovic, Arch Int Med 2008). Against this backdrop, context is needed on the 
magnitude of benefit to expect from future successful trials, and the interplay of 
cost. Recognizing the limitations of comparing results across trials and therapies, we 
assessed recent FDA solid tumor approvals showing overall survival (OS) benefit in a 
randomized trial. The objective of this analysis is to define the magnitude of benefit 
and cost of solid tumor therapies approved by FDA from 2009-2013 having phase 3 OS 
benefit. Methods: A systematic review of CenterWatch FDA-Approved Drugs and 
FDA sNDA/sBLA databases was conducted. Inclusion criteria required FDA approval 
or efficacy supplement, with OS data published 2009-2013. Hazard ratio (HR) and 
absolute and relative gain in median OS were assessed. First month drug costs were 
determined for 4Q2013, using methods previously described by Bach (NEJM 2009). 
Agents intended to be administered for £ 6 weeks were excluded from the cost 
analysis. Limitations include omission of many agents that represent important 
advances yet did not demonstrate statistically significant OS benefit relative to a 
control arm. Results: 18 FDA approved agents across 25 indications for 9 tumor 
types were assessed. The mean HR (range) and the mean relative gain in median OS 
vs trial comparator was 0.702 (0.410-0.817) and 27.91% (11.9%-67.2%), respectively. 
Medians for each measure were 0.725 and 23.6%. Mean first month treatment costs 
were $12,601 ($5,881-$50,025) with median costs of $9,282. ConClusions: Over the 
last 5 years, for FDA-approved agents for treatment of solid tumors, the magnitude 
of survival benefit, measured either as Hazard Ratio or relative gain in median OS, 
was 24-30%. This benefit, and first month costs of $9 - 13,000, may represent mid-
points of expected levels for future solid tumor agents.
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objeCtives: To describe and characterize mCRC patients who received 3rd-line 
therapy and to investigate the association of patient outcomes and treatment pat-
terns in a real-world community oncology network. Methods: This retrospective 
study utilized data from the iKnowMed™ database and billing claims. Eligibility cri-
teria included diagnosis of mCRC, initiation of 1st-line therapy between 1/1/2007 and 
6/30/2011, and initiation of 3rd-line therapy (defined as index date) before 6/30/2012. 
The key outcome was overall survival (OS). Kaplan-Meier and Cox proportional 
hazard models were used to characterize the distribution and predictors of out-
comes. Results: 757 patients were eligible for the study. The most common 3rd-line 
therapies were anti-EGFR-based (55.4%), oxaliplatin-based (13.6%), and capecitabine-
based (11.4%). OS was 8.0 (95% CI: 7.1-8.9), 8.8 (7.4-11.0), and 9.1 (6.9-11.2) months, 
respectively. Over half of patients were ≤ 65 years old (54.3%), male (55.2%), treated in 
the Southern region (61.8%), overweight/obese (56.6%), and the majority had an ECOG 
performance status ≤ 1 (78.7%). 51.8% of patients had prior comorbidities. The 5 most 
common comorbidities were hematologic, cardiovascular, gastrointestinal, neuro-
logic, and endocrine disease. KRAS testing rates at index date were 35.4% (wild-type 
26.3%, mutation 9.1%). Of KRASwild-type patients, 80.9% were treated with anti-EGFR-
based regimens which was consistent with NCCN recommendations. ConClusions: 
This comparative effectiveness study in a real-world community setting shows that 
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objeCtives: Personalized treatment for biomarker-specific breast cancer is a real-
ity. However, outcomes research has lagged behind due to lack of data sources 
capturing testing, results, and drug treatment. This study uses a new oncology elec-
tronic medical record (EMR) database to examine testing, documentation of results, 
and appropriate treatment among a cohort of women with breast cancer treated 
in community oncology practices. Methods: The Truven Health MarketScan® 
Oncology EMR Database was used to select patients diagnosed with breast cancer 
between July 1, 2011 and September 30, 2013 who had at least 2 visits and known 
disease stage. Biomarker tests and results for estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor 2 (HER2) were observed 
along with patients’ drug treatment. Results: 57,660 women met inclusion cri-
teria. Documented biomarker testing varied by disease stage and test. ER testing 
was > 90% for women with stage I or II; 77% for stage IV patients. More than 86% 
of women with stage 0-III and 71% with stage IV had a PR test. HER2 testing was 
documented in 66% with stage 0, 77% with stage I-III, and 63% with stage IV. Overall, 
74%, 55%, and 2% of women who were ER positive, HER2 positive, and HER2 nega-
tive respectively received biomarker specific treatment. Treatment rates varied by 
disease stage, with > 80% of stage IV women receiving appropriate treatment for ER 
positive or HER2 positive cancer. Among HER2 negative stage IV women, appropri-
ate treatment was 16%. 6%, 12%, and 14% of patients respectively had a biomarker 
result that was not consistent with ER positive, HER2 positive, and HER2 negative 
treatment received. ConClusions: Documentation of appropriate testing varied 
both by the type of test and disease stage. Quality improvement programs aimed 
at documentation as well as appropriate treatment may benefit patients treated in 
community oncology practice.
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objeCtives: Many studies have demonstrated that depression is associated with 
poor adherence to treatment of various diseases. Previous research has shown 
inconsistent results regarding the impact of depression on mammography use 
behaviors. The objective of this study was to assess the relationship between 
women’s depression and mammography use. To Methods: This cross-sectional 
study used data from the 2012 Behavioral Risk Factor Surveillance System (BRFSS) 
and employed the Health Belief Model (HBM). The independent variable was the 
presence of depression. The dependent variable was mammogram use, which was 
defined based on the U.S. Preventive Services Task Force’s mammogram guidelines, 
categorized at three levels: 1) had never been screened, 2) had been screened, but not 
within two years, and 3) had been screened within two years. Multivariate ordinal 
logistic regressions were used for analyses. Results: An estimated population 
size of 45,578,030 women was included. Among this population, 23.02% of women 
reported the presence of a depressive disorder. A chi-square test showed a signifi-
cant relationship between mammogram use and depression (p< 0.001). The unad-
justed proportional odds ratio [95% CI] when comparing women with depression to 
women without depression on mammogram use was 0.81 [0.76, 0.86], which means 
that both the odds of ‘screened within two years’ versus the combined ‘screened, 
but not within two years’ and ‘never screened’ and the odds of combined ‘screened 
within two years’ and ‘screened, but not within two years’ versus ‘never screened’ 
were 0.81 times lower for women with depression when compared to women with-
out depression (p< 0.001). However, when demographic and HBM characteristics 
were held constant in the regression model, the adjusted proportional odds ratio 
[95% CI] (1.05 [0.97, 1.14]) was not significant (p= 0.197). ConClusions: Depression 
itself was related to the underuse of mammography. However, after controlling 
for demographic and HBM characteristics, depression was not associated with the 
underuse of mammography.
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objeCtives: Screening of colon, stomach, bladder, prostate cancers is very relevant 
to reduce mortality. The applicable diagnosis scheme doesn’t allow detecting tumor 
processes in the early stages, later diagnosis increases cost of the next treatment, 
reducing its effectiveness and declines the length and quality of life. Methods: We 
proposed to improve diagnostics of colorectal and stomach cancer using one test; 
to apply the test for occult blood for urological field. Application of a combined test 
for determining hidden “high” and “low” bleeding in both fields displays this type 
of screening in a very interesting and economically appropriate rank. Rapid test 
for occult blood specific for human hemoglobin and transferrin is more sensitive, 
freely available in the pharmacy network, economically priced, easy to use and gives 
results on “cito”. Results: The first year results of the test use data are analyzed. 
Patients used tests purchased at their own expense. We’ve tested 88 patients for 
diagnosing possible colorectal and stomach cancer and 182 urological patients for 
diagnosing possible cancer of bladder and prostate. All 88 digestive patients test 
results for diagnosing possible colorectal and stomach cancer were negative; among 
182 tests of the urological patients we received 17 positive results, future diagnostics 
proved 7 Cr-cases and 1 with precancerous (is under control). Such data does not 
allow yet statistic analysis. ConClusions: The project is under implementation. 
For 7 Cr-diagnosed patients the treatment allows almost twice increase of expected 
life time and the 8-th patient may become our first preventive Cr-case. Proved effi-
ciency of the screening algorithm would become a basis for changing the national 
standard of medical care in Lviv region and Ukraine in general.
